BACKGROUND: Recombinant factor VIIa (rFVIIa, Novoseven) is currently used to control bleeding in hemophiliacs with inhibitors. A new rFVIIa variant, NN1731, with increased activity on the surface of activated platelets, has demonstrated a more potent and faster onset of reactivity than rFVIIa in various in vitro models. The present study aimed to investigate whether this translates into greater efficacy and faster promotion of hemostasis in vivo. METHOD AND RESULTS: In a severe tail-bleeding model in hemophilia A mice, NN1731 demonstrated significantly greater efficacy than rFVIIa, plasma-derived activated prothrombin complex concentrate (pd-aPCC, FEIBA or FVIII (Refacto). Assessment of the blood loss over time showed that NN1731 significantly and dose-dependently reduced the blood loss in the first 5-min observation period, whereas the effect of rFVIIa, FVIII and pd-aPCC first became evident 5-10 min after injury. CONCLUSION: This study shows that NN1731 has a greater efficacy and faster resolution of bleeding in a severe bleeding model in hemophilia A mice compared with any of the other agents tested.
BACKGROUND: Recombinant factor VIIa (rFVIIa, Novoseven) is currently used to control bleeding in hemophiliacs with inhibitors. A new rFVIIa variant, NN1731, with increased activity on the surface of activated platelets, has demonstrated a more potent and faster onset of reactivity than rFVIIa in various in vitro models. The present study aimed to investigate whether this translates into greater efficacy and faster promotion of hemostasis in vivo. METHOD AND RESULTS: In a severe tail-bleeding model in hemophilia A mice, NN1731 demonstrated significantly greater efficacy than rFVIIa, plasma-derived activated prothrombin complex concentrate (pd-aPCC, FEIBA or FVIII (Refacto). Assessment of the blood loss over time showed that NN1731 significantly and dose-dependently reduced the blood loss in the first 5-min observation period, whereas the effect of rFVIIa, FVIII and pd-aPCC first became evident 5-10 min after injury. CONCLUSION: This study shows that NN1731 has a greater efficacy and faster resolution of bleeding in a severe bleeding model in hemophilia A mice compared with any of the other agents tested.
Authors: Keith Gomez; Robert Klamroth; Johnny Mahlangu; Maria E Mancuso; María E Mingot; Margareth Castro Ozelo Journal: Blood Transfus Date: 2013-12-03 Impact factor: 3.443
Authors: Laura D Gray; Michael A Hussey; Brittany M Larson; Kellie R Machlus; Robert A Campbell; Gary Koch; Mirella Ezban; Ulla Hedner; Alisa S Wolberg Journal: Thromb Res Date: 2011-05-10 Impact factor: 3.944
Authors: Lars C Petersen; Ditte M Karpf; Henrik Agersø; Mette B Hermit; Hermann Pelzer; Egon Persson; Timothy C Nichols; Mirella Ezban Journal: Br J Haematol Date: 2010-11-18 Impact factor: 6.998
Authors: Marisa A Brake; Lacramioara Ivanciu; Susan A Maroney; Nicolas D Martinez; Alan E Mast; Randal J Westrick Journal: Curr Protoc Mouse Biol Date: 2019-03-15
Authors: Anders L Nielsen; Anders B Sorensen; Heidi L Holmberg; Prafull S Gandhi; Johan Karlsson; Jens Buchardt; Kasper Lamberth; Mads Kjelgaard-Hansen; Carsten Dan Ley; Brit B Sørensen; Wolfram Ruf; Ole H Olsen; Henrik Østergaard Journal: Proc Natl Acad Sci U S A Date: 2017-11-06 Impact factor: 11.205